Raquel Hontecillas

Raquel Hontecillas has 17 years of translational experience in the biotech industry focusing on infectious, immune-mediated, and metabolic diseases. She has identified and validated the role of the Lanthionine Synthetase C like 2 (LANCL2) pathway as a key therapeutic target for diabetes and inflammatory bowel disease.

Raquel expanded Biotherapeutics Inc.‘s product pipeline with other novel targets and therapeutics. She published over 100 peer-reviewed papers, 5 patents and manages an R&D portfolio of $15 million.